A combination of two topical drugs triggers a robust immune response against precancerous skin lesions, aiding in skin cancer prevention. The research, from the Washington University School of Medicine in St. Louis and Harvard Medical School, shows t ...
New research shows that excess weight increases the risk that a benign blood disorder will progress into multiple myeloma, a cancer of the blood. The study, by a team at Washington University School of Medicine in St. Louis, is ...
A blood test could predict how well small-cell lung cancer (SCLC) patients will respond to treatment, according to new research published in Nature Medicine. Scientists, based at the Cancer Research UK Manchester Institute at The University of Man ...
A University of Liverpool research team has published a study that identifies the mechanism in the human body that causes resistance of pancreatic cancer cells to chemotherapy, focusing on Fibroblasts in pancreatic cancer. Pancreatic cancer is one ...
Most media attention is awarded to cancer's success stories - new treatment breakthroughs are celebrated as researchers (and journalists) search for an exciting new "cure" for cancer. But what happens after these innovations hit the news? And who is ...
Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells, representing a significant advancement in T-Cell L ...
A diagnosis of pancreatic cancer is often a death sentence because chemotherapy and radiation have little impact on the disease. In the U.S. this year, some 53,000 new cases will be diagnosed, and 42,000 patients will die of the disease, according to ...
Get today's drug discovery & development headlines and news - Sign up now! Taking aspirin reduces a person’s risk of colorectal cancer, but the molecular mechanisms involved have remained unknown until a recent discovery by The Hormel Institute, ...
For the first time, it has been shown that many mutations in tumors--20 percent—are immunogenic, or able to rouse armies of T cells, post-vaccine. Also for the first time, it has been shown that most of those roused T cell armies are helper CD4+ T ce ...
Vanderbilt University researcher William Mitchell, M.D., Ph.D., and colleagues in Germany and Canada have demonstrated a method for detecting “cell-free” tumor DNA in the bloodstream. Mitchell believes the technique will be transformative in provid ...